A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.

MLA

Liang, Yu-Jing, et al. “A Phase II Randomised Controlled Trial of Adjuvant Tumour-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-Selected High-Risk Nasopharyngeal Carcinoma Patients.” European Journal of Cancer (Oxford, England : 1990), vol. 191, Sept. 2023, p. 112965. EBSCOhost, https://doi.org/10.1016/j.ejca.2023.112965.

APA

Liang, Y.-J., Chen, Q.-Y., Xu, J.-X., Liu, X.-F., Xia, J.-C., Liu, L.-T., Guo, S.-S., Song, B., Wang, P., Li, J.-B., Liu, Q., Mo, H.-Y., Guo, L., Sun, R., Luo, D.-H., He, J., Liu, Y.-N., Nie, C.-P., Tang, L.-Q., … Mai, H.-Q. (2023). A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients. European Journal of Cancer (Oxford, England : 1990), 191, 112965. https://doi.org/10.1016/j.ejca.2023.112965

Chicago

Liang, Yu-Jing, Qiu-Yan Chen, Jing-Xiao Xu, Xiu-Feng Liu, Jian-Chuan Xia, Li-Ting Liu, Shan-Shan Guo, et al. 2023. “A Phase II Randomised Controlled Trial of Adjuvant Tumour-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-Selected High-Risk Nasopharyngeal Carcinoma Patients.” European Journal of Cancer (Oxford, England : 1990) 191 (September): 112965. doi:10.1016/j.ejca.2023.112965.